Management of cutaneous lymphoma.
The foregoing underlines the advances which have been made in our understanding of cutaneous lymphoma and the areas where further research is needed. With a few noteable exceptions the aim of therapy in CTCL is palliative rather than curative and treatment success is measured in terms of disease-free interval. There is still no evidence that any chemotherapeutic regimen prolongs survival. A possible exception is the effect of photopheresis in Sézary syndrome but our own experience differs from that in the USA and underlines the need to identify patients with clonal disease when defining subjects for study. The combination of genotypic analysis and new treatment methods offers exciting new prospects in the management of patients with cutaneous lymphoma.
Russell-Jones
R
R
Skin Tumour Unit, St John's Institute of Dermatology, St Thomas' Hospital, London, UK.
Spittle
M F
MF
D006801:Humans; D008223:Lymphoma / Q000145:classification / Q000503:physiopathology / Q000628:therapy; D012878:Skin Neoplasms / Q000145:classification / Q000503:physiopathology / Q000628:therapy